HUTCHMED (China) (HMDCF) Divestments (2021)
HUTCHMED (China)'s (HMDCF) quarterly Divestments came in at $159.1 million in Q3 2021, up 1325733.33% quarter-over-quarter from $12000.0 in Q2 2021.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Divestments (2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Divestments for 1 consecutive years, with $159.1 million the latest figure, recorded in Q3 2021.
- On a quarterly basis, Divestments changed N/A year-over-year to $159.1 million in Q3 2021; TTM through Sep 2021 was $159.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$476.9 million, changed N/A from the prior year.
- Divestments was $159.1 million for Q3 2021 at HUTCHMED (China), up from $12000.0 in the prior quarter.
- Over five years, Divestments peaked at $159.1 million in Q3 2021 and troughed at $12000.0 in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 28, 2021 | 159.10 Mn |
| Jun 30, 2021 | 12,000.00 |
| Mar 31, 2021 | 15.90 Mn |